KATHLEEN MICIANO: Open Payments
NPI 1477110260 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$280 in 13 payments from 8 companies in 2025. Trend: 2023 $200 · 2024 $0 · 2025 $280
Food & beverage: $280
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 3 | $64 |
| Novo Nordisk Inc | 2 | $45 |
| Sumitomo Pharma America, Inc. | 2 | $37 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| ABBVIE INC. | 1 | $30 |
| Novartis Pharmaceuticals Corporation | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| TOLMAR, INC. | 1 | $18 |
Products named: Symbravo, GEMTESA, AIRSUPRA, QULIPTA, LEQVIO, Wegovy, REXULTI, Ozempic.
Industry payments across TX — which companies pay providers there.
